

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

SECTION 1. IDENTIFICATION

Product name : Betamethasone (0.05%) Ointment Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Reproductive toxicity : Category 1B

Specific target organ systemic toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus, Blood, Adrenal gland)

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.
H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus, Blood, Adrenal gland) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	≥ 70 - < 90
Propylene glycol	57-55-6	≥ 10 - < 20
Betamethasone	378-44-9	≥ 0.01 - < 0.1

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Vapors may form explosive mixtures with air. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Betamethasone (0.05%) Ointment Formulation

Version 2.0 Revision Date: 09/14/2017 SDS Number: 1681972-00002 Date of last issue: 05/18/2017
 Date of first issue: 05/18/2017

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
 Do not swallow.
 Avoid contact with eyes.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Keep container tightly closed.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Keep tightly closed.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m ³	OSHA Z-1
		TWA (Inhalable fraction)	5 mg/m ³	ACGIH
		TWA (Mist)	5 mg/m ³	NIOSH REL
		ST (Mist)	10 mg/m ³	NIOSH REL
Propylene glycol	57-55-6	TWA	10 mg/m ³	US WEEL
Betamethasone	378-44-9	TWA	1 µg/m ³ (OEB 4)	Merck
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Merck

- Engineering measures : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
 All engineering controls should be implemented by facility

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : ointment

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Color	:	white to off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 93.3 °C
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle size	:	Not applicable

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Vapors may form explosive mixture with air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:**Petrolatum:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity Remarks: Based on data from similar materials

Propylene glycol:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rabbit): > 159 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Betamethasone:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
---------------------	---	---------------------------

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
Exposure time: 4 h**Skin corrosion/irritation**

Not classified based on available information.

Ingredients:**Petrolatum:**Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Remarks: Based on data from similar materials**Propylene glycol:**Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation**Betamethasone:**Species: Rabbit
Result: Mild skin irritation**Serious eye damage/eye irritation**

Not classified based on available information.

Ingredients:**Petrolatum:**Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405
Remarks: Based on data from similar materials**Propylene glycol:**Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405**Betamethasone:**Species: Rabbit
Result: No eye irritation**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Respiratory sensitization

Not classified based on available information.

Ingredients:**Petrolatum:**

Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

Propylene glycol:

Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Betamethasone:

Routes of exposure: Dermal
Species: Guinea pig
Result: Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Ingredients:**Petrolatum:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

Propylene glycol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Betamethasone:

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Result: negative Test Type: Chromosome aberration test in vitro Result: positive
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Ingredients:**Petrolatum:**

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Propylene glycol:

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child.

Ingredients:**Petrolatum:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Species: Rat
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Skin contact
 Result: negative
 Remarks: Based on data from similar materials

Propylene glycol:

Effects on fertility : Test Type: Three-generation reproduction toxicity study
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Betamethasone:

Effects on fetal development : Species: Rabbit
 Application Route: Intramuscular
 Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
 Result: Fetotoxicity., Malformations were observed.

Species: Rat
 Application Route: Subcutaneous
 Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
 Result: Malformations were observed.

Species: Mouse
 Application Route: Intramuscular
 Developmental Toxicity: LOAEL: 1 mg/kg body weight
 Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus, Blood, Adrenal gland) through prolonged or repeated exposure.

Ingredients:

Betamethasone:

Target Organs: Pituitary gland, Immune system, muscle, thymus, Blood, Adrenal gland
 Assessment: Causes damage to organs through prolonged or repeated exposure.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

II**Repeated dose toxicity****Ingredients:****Petrolatum:**

Species: Rat
NOAEL: 5,000 mg/kg
Application Route: Ingestion
Exposure time: 2 y

Propylene glycol:

Species: Rat, male
NOAEL: 1,700 mg/kg
Application Route: Ingestion
Exposure time: 2 y

Betamethasone:

Species: Rabbit
LOAEL: 0.05 %
Application Route: Skin contact
Exposure time: 10 - 30 d
Target Organs: Pituitary gland, Immune system, muscle

Species: Rat
LOAEL: 0.05 %
Application Route: Skin contact
Exposure time: 8 Weeks
Target Organs: thymus

Species: Mouse
LOAEL: 0.1 %
Application Route: Skin contact
Exposure time: 8 Weeks
Target Organs: thymus

Species: Dog
LOAEL: 0.05 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Blood, thymus, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Ingredients:****Betamethasone:**

Inhalation : Target Organs: Adrenal gland

Skin contact : Symptoms: Redness, pruritis, Irritation

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

II

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Ingredients:

Petrolatum:

Toxicity to fish	: LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 10,000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae	: NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 10 mg/l Exposure time: 21 d Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Propylene glycol:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l Exposure time: 48 h
Toxicity to algae	: ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l Exposure time: 7 d
Toxicity to microorganisms	: NOEC (Pseudomonas putida): > 20,000 mg/l Exposure time: 18 h

Betamethasone:

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): > 50 mg/l Exposure time: 96 h
--	---

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l
Exposure time: 219 d
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1,000

Persistence and degradability**Ingredients:****Petrolatum:**

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

Propylene glycol:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 98.3 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

Bioaccumulative potential**Ingredients:****Propylene glycol:**

Partition coefficient: n-octanol/water : log Pow: -1.07

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

Betamethasone:

Partition coefficient: n-octanol/water : log Pow: 2.11

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone)

Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Betamethasone)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Betamethasone)

Class : 9
Packing group : III
Labels : 9

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

|| EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

UN/ID/NA number : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Betamethasone)
|| Class : 9
Packing group : III
Labels : CLASS 9
|| ERG Code : 171
Marine pollutant : yes(Betamethasone)
|| Remarks : Above applies only to containers over 119 gallons or 450
liters., Shipment by ground under DOT is non-regulated;
however it may be shipped per the applicable hazard
classification to facilitate multi-modal transport involving ICAO
(IATA) or IMO.

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

|| **SARA 311/312 Hazards** : Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with
known CAS numbers that exceed the threshold (De Minimis)
reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

Petrolatum	8009-03-8
Propylene glycol	57-55-6
Hydrocarbon wax	8001-75-0

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

California List of Hazardous Substances

Petrolatum 8009-03-8

California Permissible Exposure Limits for Chemical Contaminants

Petrolatum 8009-03-8


The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
US WEEL	:	USA. Workplace Environmental Exposure Levels (WEEL)
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / ST	:	STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
OSHA Z-1 / TWA	:	8-hour time weighted average
US WEEL / TWA	:	8-hr TWA

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Sub-

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/18/2017
2.0	09/14/2017	1681972-00002	Date of first issue: 05/18/2017

stances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/14/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8